Close Menu

DxTerity Diagnostics

The company is combining digital recruiting methods with at-home sample collection to speed up the study process.

The Biomedical Advanced Research and Development Authority aims to produce at least two US Food and Drug Administration-cleared tests.

DxTerity aims to develop a genomic blood test to identify which cancer patients are most likely to benefit from radiation therapy or are at risk for toxicity.

The firm plans to seek Emergency Use Authorization for the 18-gene panel and will subsequently submit it to the FDA for full approval.

The firm will use the money from SWK Funding to commercialize its DxDirect genomic testing platform and its DxCollect MicroCollection Device.

The additional funds bring the total contract to $43 million over approximately eight years.

With eight independently programmable amplification wells, the firm's portable PCR platform is now in small-scale production.

Molecular diagnostics company DxTerity Diagnostics was recently awarded a $280,000 Small Business Innovation Research contract from the National Cancer Institute to develop a test for susceptibility to radiation sickness during cancer treatment.

DxTerity Diagnostics has developed a rapid assay for analyzing gene expression of as many as 100 genes directly from small amounts of formalin-fixed, paraffin-embedded clinical samples without prior RNA extraction.

Pages

Retraction Watch reports that a paper was pulled because it refers to a gene that doesn't exist in mice.

Researchers were able to generate fertilized northern white rhinoceros eggs, according to Mashable.

Former Orig3n employees raise concerns about its testing at Bloomberg Businessweek.

In PLOS this week: microRNA expression changes in hepatocellular carcinoma, real-time PCR-based approach for diagnosing schistosomiasis, and more.